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K-Ras is the most famous oncogene that is frequently mutated in human 
cancers, and it influences on poor prognosis with low survival rate of cancer 
patients. Although K-Ras is a strong target of cancer therapeutics, the 
mechanism underlying pathological increase of K-Ras is unclear. Here we 
report that AIMP2-DX2, oncogenic splicing variant of AIMP2-F, is critical 
determinant of K-Ras stabilization. Through transcriptome analysis in 
AIMP2-DX2 high- and low-expressing lung cancer cells, we identified 
AIMP2-DX2 is positively correlated with Ras signaling. In AIMP2-DX2-
inducible in vitro and in vivo model, we monitored the stabilization of K-
Ras by induction of AIMP2-DX2. AIMP2-DX2 GST-N domain binds to the 
positively charged hypervariable region of K-Ras and inhibits the β-TrCP-, 
E3 ligase of K-Ras, mediated ubiquitination. Therefore, this work unveiled 
that the stabilization of K-Ras can be determined by interaction with 
AIMP2-DX2 and suggested that the interaction of two oncogenic proteins 
leads to pathologically synergic cancer-promoting property.
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INTRODUCTION
Ras protein is a critical protein of signal cascade in proliferative condition. 
Ras proteins are regulated by guanine nucleotide exchange factors (GEF) 
that promote GDP dissociation and GTP binding, and GTPase-activating 
proteins (GAP) that stimulate the GTPase activity of Ras (1). In human 
cancer, Ras genes are frequently mutated and function as oncogenes.
Aberrant Ras function is associated with a single mutation typically at 
codon 12, 13, or 61 in cancer (2). Ras with the single mutation leads to 
constitutive activation of Ras by blocking GAP binding. When Ras is the 
active form, Ras-GTP can bind to numerous effectors. In the active GTP-
bound state, Ras proteins interact with downstream effectors, such as Raf, 
Ral-GEF and PI3K (phosphoinositide 3-kinase), to transmit signals from the 
cell membrane to intracellular signaling pathways that ultimately influence 
gene transcription and therefore regulate cellular function related on 
proliferation, survival, and angiogenesis (3). Also, there is evidence to 
suggest that Ras activity is regulated by other mechanisms, such as its 
ubiquitination-dependent stability (4).
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Three RAS genes encode four proteins: K-Ras4A, K-Ras4B, N-Ras, 
and H-Ras (5). All Ras isoforms share sequences in all of the regions that 
are related with GDP/GTP binding, GTPase activity, and effector 
interactions (6). Nevertheless, Ras proteins have isoform-specific functions. 
These functional differences are most likely associated with the unique C-
terminal hypervariable region (HVR) in each isoform, which is thought to 
modulate the Ras–membrane interaction to specify distinctive localizations
(7). Also, although N-ras and H-ras, after palmitoylation, traffic through the 
classical secretory pathway through the Golgi to the plasma membrane, K-
ras traffics to the plasma membrane through a poorly characterized pathway 
that bypasses the Golgi (8). 
MSC (multi-synthetase complex) is composed of nine ARSs 
(aminoacyl tRNA synthetase), enzyme which ligates the specific amino acid 
and its cognate tRNA, and AIMP1, 2, and 3, three auxiliary factors (9). 
Three AIMPs facilitate the assembly of MSC through the interactions with 
each other as well as with their specific target enzymes (10). In addition to 
stabilization of MSC, these factors also play the regulatory roles in signaling 
pathways (11, 12). Especially, upon DNA damage, AIMP2 is dissociated 
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from the complex and works as a potent tumor suppressor by promoting
apoptosis through the protective interaction with p53 (13, 14). 
However, AIMP2 produces a variant lacking a part of its structure 
in cancer, and it was designated as AIMP2-DX2. The splicing variant of 
AIMP2 lacking exon 2 (AIMP2-DX2) blocks the tumor suppressive activity 
of AIMP2 full length (AIMP2-F) by competitive binding to p53 (15). 
Moreover, many cancer cell lines and patients shows the higher expression 
of AIMP2-DX2 than normal. Additionally, the patients with higher 
expression of AIMP2-DX2 showed lower survival and poor prognosis. 
Suppression of AIMP2-DX2 inhibited tumor growth, suggesting it as a new 
therapeutic target (15).
In this work, we found the functional connection of two oncogenic 
proteins, AIMP2-DX2 and Ras. Positive correlation between AIMP2-DX2 
and Ras was identified by transcriptomic analysis. Through the interaction 
screening of all the Ras isoforms, the specific interaction of AIMP2-DX2 to 
K-Ras was confirmed and that binding enhances the stability of K-Ras 
proteins. Also, in in vitro and in vivo AIMP2-DX2-inducible system, 
AIMP2-DX2 induction leads to stabilization of K-Ras. Therefore, this study 
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indicates a potential mechanism for tumor promotion by synergistic effect of 
two oncogenic proteins, K-Ras and AIMP2-DX2.
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Results
Positive connection between AIMP2-DX2 and Ras signaling
To identify the insight how AIMP2-DX2 affects cancer progression, we 
analyzed the genetic background in AIMP2-DX2 high- or low-expressing 
lung cancer cell lines. Through transcriptome analysis to check the 
differentially expressed genes in those cells, we found some significant
differences on the level of genes which are related with AIMP2-DX2 levels
(Figure 1A). Interestingly, we identified that the proliferative and apoptotic 
genes are upregulated and downregulated in AIMP2-DX2 high-expressing 
cells, respectively (Figure 1B). And also the signals of Ras-upstream and -
downstream gene expression are specifically increased in cell lines with 
high expression of AIMP2-DX2 (Figure 1C).
AIMP2-DX2 specifically increases not N- and H-Ras but K-Ras of 
protein level regardless of mutation
To study the meaning of positive correlation of AIMP2-DX2 and Ras, we 
checked whether AIMP2-DX2 enhances endogenous Ras protein in H460 
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cells. And then, we found that AIMP2-DX2 increases endogenous Ras on 
protein level (Figure 2A). Also, to further study, we cloned all the Ras 
isoforms and each frequent mutant in major cancers (Figure 2B). All GFP-
Ras isoform wild types (WT) and each cancer-associated mutant were 
expressed in HEK 293T cells in presence or absence of strep-AIMP2-DX2, 
and the amounts of GFP were determined by immunoblotting. Specifically, 
AIMP2-DX2 increased the expression of K-Ras only, neither N-Ras nor H-
Ras. Moreover, AIMP2-DX2-mediated increases of K-Ras seem to be 
totally irrelevant to mutation. Also, we checked whether AIMP2-DX2-
mediated increase of K-Ras happen on transcription level. But, AIMP2-DX2 
does not affect the level of Ras mRNA. We concluded that AIMP2-DX2 
increases K-Ras on protein level (Figure 2C).
AIMP2-DX2 enhances the stability of K-Ras
As we found that AIMP2-DX2 increases K-Ras protein expression, we 
investigated whether AIMP2-DX2 enhances the stability of Ras and 
contributes to its ubiquitination. To check up the stability of Ras protein, we 
treated the cycloheximide time-dependently, and we monitored that the 
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cellular stability of K-Ras, not N- and H-Ras, is only enhanced in condition 
of AIMP2-DX2 overexpression (Figure 3A, 3B). Moreover, as Ras protein 
is degraded by ubiquitin-dependent proteasomal degradation (16), we 
checked the ubiquitination of Ras isoforms in HEK 293T cells in presence 
or absence of strep-AIMP2-DX2. Likewise, in AIMP2-DX2-overexpressing 
cells we observed the decreased amount of K-Ras ubiquitination, not N- and 
H-Ras (Figure 3C).
To confirm the effect of AIMP2-DX2 on endogenous K-Ras in 
cancer cells, we established strep-AIMP2-DX2 inducible stable cell line 
with H460, lung cancer cell line. In order to induce AIMP2-DX2, we treated 
doxycycline time-dependently and monitored the expression of the induced 
AIMP2-DX2 and endogenous K-Ras. We found that endogenous K-Ras 
protein level followed the increase of AIMP2-DX2 (Figure 4A). Also this 
result was confirmed in vivo. We manufactured the AIMP2-DX2-inducible 
mouse and we checked up the expression of AIMP2-DX2 and endogenous 
K-Ras in spleen of a transgenic mouse. As above, the similar effect of 
inducible AIMP2-DX2 on the endogenous K-Ras was also observed in the 
mouse spleen (Figure 4B).
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Specific interaction between AIMP2-DX2 and K-Ras
As we found that AIMP2-DX2 stabilizes K-Ras, we investigated whether 
AIMP2-DX2 binds to K-Ras. Through binding screening using 
immunoprecipitation with all the Ras isoform wild types and mutants, we 
found that only K-Ras binds with AIMP2-DX2 regardless of mutation, not 
N- and H-Ras (Figure 5A). Next, we also checked up the imaging assay 
using confocal microscopy. Through the immunofluorescence experiment, 
we observed that all the tested GFP-K-Ras wild types and mutant types
were co-localized with RFP-AIMP2-DX2, and this result was as same as 
immunoprecipitation (Figure 5B). Altogether, AIMP2-DX2 specifically 
interacts with K-Ras.
Positive patch of K-Ras HVR is critical for interaction with AIMP2-
DX2
To investigate which peptide region of AIMP2-DX2 is critical for its
interaction with K-Ras, we performed domain mapping using various 
AIMP2-DX2 deletion mutants by in vitro pull down assay. We purified 
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GST-proteins containing AIMP2-DX2 1-87, 88-151, 152-251, 1-151 and 88-
251 amino acids (Figure 6A), and each purified protein was mixed with the 
lysate expressing GFP-K-Ras4B wild type. Through the result of in vitro
pull down assay, we observed GFP-K-Ras4B wild type binds to peptide 
region containing AIMP2-DX2 88-151 amino acids (Figure 6B). This result 
shows that 88-151 region of AIMP2-DX2, GST N-terminal domain, is 
critical for binding with K-Ras. To find the information of this binding 
region, we checked the structure of K-Ras and GST domain of AIMP2-DX2. 
Specifically, although the structures of the G domain of K-, N- and H-Ras, 
are almost identical, K-Ras only has positively charged patch in 
hypervariable region (HVR) (Figure 6C). Moreover, through the structural 
analysis of AIMP2-DX2 GST domain, we found that GST domain of 
AIMP2-DX2 has negatively charged patch (Figure 6D). Hence, we suggest 
that the each opposite charge peptide region of AIMP2-DX2 and K-Ras is 
critical for the interaction, but the validation is needed. 
AIMP2-DX2 inhibits the β-TrCP-mediated ubiquitination of K-Ras
AIMP2-DX2 enhances the protein stability of K-Ras, and protein stability is 
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usually controlled by proteasome-dependent degradation. Because β-TrCP
was reported as an E3 ligase of Ras protein in previous study (16), we tested 
whether AIMP2-DX2 affects β-TrCP-mediated degradation. First, we 
checked whether AIMP2-DX2 suppress the β-TrCP-dependent turnover of 
K-Ras. We observed that β-TrCP-mediated degradation of K-Ras is 
recovered by overexpression of AIMP2-DX2 (Figure 7A). Next, we checked 
the ubiquitination of K-Ras. Likewise, the amount of ubiquitinated K-Ras 
by β-TrCP is declined when AIMP2-DX2 was exogenously introduced 
(Figure 7B). Lastly, we investigated whether AIMP2-DX2 inhibits
interaction between K-Ras and β-TrCP, substrate and E3 ligase, respectively. 
In the immunoprecipitation, when AIMP2-DX2 was overexpressed, binding 
of β-TrCP to K-Ras was decreased (Figure 7C). Altogether, AIMP2-DX2 
inhibits the interaction between K-Ras and β-TrCP, resulting in suppression 
of ubiquitination of K-Ras.
All of these results suggest that AIMP2-DX2 enhances the stability 
of K-Ras via interaction with K-Ras. In AIMP2-DX2 overexpression 
condition, like cancer, the binding of AIMP2-DX2 to K-Ras blocks the 
approach of β-TrCP, E3 ligase, and then, it leads to stabilization of K-Ras. 
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That results in synergic oncogenic property through connecting with two 
oncogenic proteins, AIMP2-DX2 and K-Ras (Figure 8).
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DISCUSSION
This study proposes AIMP2-DX2, oncogenic protein, as a key determinant 
required in the K-Ras-stabilizing effect. Through transcriptome analysis, we 
found that AIMP2-DX2 is positively associated with Ras signaling. And, it 
was also found that AIMP2-DX2 specifically binds to K-Ras and increases 
K-Ras, not N- and H-Ras, of protein level, regardless of mutation. AIMP2-
DX2 is a positive regulator contributed to the stabilization of K-Ras by 
inhibiting the recruitment of β-TrCP, E3 ligase, with K-Ras. The mechanism 
implies AIMP2-DX2 stabilizing K-Ras and amplifying the signal 
transductions of oncogenic K-Ras. To further study on synergistic 
oncogenecity of two proteins via Ras stabilization, in vitro and in vivo
phenotype analysis, and patient analysis need to be performed. Also, as K-
Ras has oncogenic properties through its downstream signal transduction 
related on proliferation and survival, influences of AIMP2-DX2 on 
downstream effectors of K-Ras need to be involved in further study.
Aberrant Ras function is associated in various cancers. As the 
mechanisms underlying increase of pathological level of K-Ras are unclear, 
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many clinical trials targeting K-Ras yielded disappointing results. However, 
this study shows AIMP2-DX2 suppresses the degradation of K-Ras, 
regardless of mutation, and it means AIMP2-DX2-targeting will be covered 
both wild type and mutant of K-Ras degradation. Therefore, this study is a 
highly significant discovery that unveils the mechanism of pathological K-
Ras stabilization.
Our results are meaningful in the aspect that a gain-of-function of 
AIMP2-DX2 was unveiled for the first time. Oncogenic roles of AIMP2-
DX2 have been limited to blocker of AIMP2-F since it was found that 
AIMP2-DX2 is an alternative splicing form of AIMP2-F. The role of 
AIMP2-DX2 related to K-Ras stabilization is distinguishable from that of 
AIMP2-F. These results will be used for the basis on the study of oncogenic 
AIMP2-DX2. And, the connection between AIMP2-DX2 and K-Ras implies 
the synergistic oncogenecity of two proteins.
Based on the results from this study, AIMP2-DX2 could be a novel 
target in various cancers that K-Ras is crucial such as pancreatic cancer, 
colorectal cancer and lung cancer. Additionally, interaction between AIMP2-
DX2 and K-Ras supposes new approaches toward drug development on 
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targeting K-Ras. Downregulation of AIMP2-DX2 via targeting it has two 
merits: 1) Decrease of AIMP2-DX2 leads to decline of oncogenic protein K-
Ras since the result of this study, AIMP2-DX2-mediated stabilization 
mechanism of K-Ras. 2) Since AIMP2-DX2 blocks the tumor suppressor 
activity of AIMP2-F in various signals, decline of AIMP2-DX2 leads to the 
enhanced tumor suppressor activity of AIMP2-F, resulting in regression of 
cancer. This study gives a solution, or suggests a potential candidate that 
could be an efficacious therapeutic medicine for suffering patients from the 
absence of proper drugs. Therefore, we propose possibility of new therapy 
related with K-Ras by targeting AIMP2-DX2. Targeting AIMP2-DX2 will 
be significant in treatments for major cancers without good drugs. 
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Figure 1. AIMP2-DX2 is positively associated with Ras signaling
(A) Gene signature by transcriptome analysis to find DEG 
(differentially expressed genes) in AIMP2-DX2 low or AIMP2-DX2 high
lung cancer cell lines. The expression of AIMP2-DX2 in 18 lung cancer 
cell lines was analyzed by western blotting. Green and red signature 
means the increased and decreased gene expression, respectively. 
(B) Differentially expressed proliferative or apoptotic genes in AIMP2-
DX2 high or low cell lines are classified and displayed.
(C) Signals of Ras-upstream and -downstream gene expression are 
specifically increased.
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Figure 2. AIMP2-DX2 specifically increases K-Ras not N- and H-Ras 
of protein level regardless of mutation
(A) AIMP2-DX2 increases endogenous Ras protein level in H460 cells. 
(B) Ras isoform-specific point mutation and disease.
(C) GFP-Ras isoforms wild type (WT) and each mutant were expressed 
in HEK 293T cells in presence or absence of strep-AIMP2-DX2, and the 
amounts of GFP were determined by immunoblotting. Actin was used 
as a loading control. S.E. and L.E. means short expose and long expose, 
reslectively. Also, Same cells as above were subjected to RT-PCR for 
checking the mRNA level of Ras. Actin was used as a loading control of 
RT-PCR.
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Figure 3. AIMP2-DX2 enhances the stability of K-Ras
(A and B) The cellular stability of GFP-Ras isoforms wild type (WT) 
was determined by treatment of cycloheximide (CHX) time-
dependently as indicated above. The amounts of Ras were determined 
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by immunoblotting using antibody against GFP (A). Results of 
immunoblotting were quantified and displayed as a graph (B). Actin 
was used as a loading control.
(C) The effect of AIMP2-DX2 on ubiquitination of Ras was confirmed. 
The same cells as above were treated with MG-132 for 4 hours and 
subjected to ubiquitination assay.
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Figure 4. AIMP2-DX2 enhances the stabilization of K-Ras
(A) AIMP2-DX2-inducible H460 cells were treated with doxycycline 
(Dox) time-dependently for induction of AIMP2-DX2. The expression of 
K-Ras and AIMP2-DX2 were checked by western blotting using their
specific antibodies. EV means empty vector for using negative control to 
AIMP2-DX2. Actin was used as a loading control.
(B) AIMP2-DX2-inducible mouse was treated with doxycycline (Doxy) 
time-dependently or not, and spleen of sacrificed mouse was analyzed 
by immunoblotting. Experimental schedule of AIMP2-DX2 turn on or 
off was shown in right table.
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Figure 5. AIMP2-DX2 binds to K-Ras
(A) Interaction of AIMP2-DX2 with GFP-Ras isoforms wild type (WT) 
and each mutant was confirmed by co-immunoprecipitation. GFP-Ras-
expressing HEK 293T cells were introduced by strep-AIMP2-DX2 and 
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the cells were subjected to immunoprecipitation with GFP-tag column. 
Co-precipitated AIMP2-DX2 with Ras was analyzed by western blotting 
using antibody against Strep.
(B) RFP-AIMP2-DX2 and GFP-Ras isoforms wild type or mutant type
were expressed in HEK 293T cells. Colocalization of two proteins was 
monitored with GFP and RFP by using confocal microscopy. DAPI 
staining means the nucleus.
25
Figure 6. Negative patch of AIMP2-DX2 interacts with positive patch of 
K-Ras hyper variable region (HVR)
(A) Domain arrangement of AIMP2-DX2 and K-Ras protein. AIMP2-
DX2 is composed of three peptide region as indicated. 
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(B) GST proteins containing 1-87, 88-151, 152-251, 1-151 and 88-251 
amino acids region of AIMP2-DX2 were purified. Each purified GST 
protein was incubated with extracts from HEK 293T cells expressing 
GFP-K-Ras4B wild type (WT) and pulled down with Glutathione 
Sepharose beads. The precipitated Ras was detected by western blotting 
using anti-GFP antibody. The amounts of each purified GST proteins 
were determined by coomassie staining.
(C) Domain arrangement of Ras isoforms wild type (WT). The 
structures of the G domain of K-, N- and H-Ras have been solved and 
are virtually identical, but the structure of processed hypervariable 
regions (HVR) has not been solved and is depicted as a linear sequence. 
K-Ras only has positively charged patch. 
(D) The structure of GST domain of AIMP2-F. Negatively and 
positively charged patch was shown as red and blue colors, respectively.
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Figure 7. AIMP2-DX2 inhibits the β-TrCP-mediated ubiquitination of 
K-Ras
(A) The effect of AIMP2-DX2 on β-TrCP-mediated degradation of K-
Ras. Each plasmid as indicated was expressed in HEK 293T cells and 
the cells were subjected to SDS-PAGE. The expression of each protein 
was checked by immunoblotting with its specific antibody. Tubulin was 
used as a loading control.
(B) The effect of AIMP2-DX2 on β-TrCP-mediated ubiquitination of K-
Ras. The same cells as above expressed exogenous HA-Ub and were 
treated with MG-132 for 4 hours. The cells were subjected to 
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ubiquitination assay. The amounts of ubiquitinated K-Ras were
determined by immunoblotting with the antibody against HA. Actin 
was used as a loading control.
(C) The effect of AIMP2-DX2 on the interaction between β-TrCP and 
K-Ras. Indicated plasmids were expressed into HEK 293T cells and K-
Ras was precipitated with strep-tag column. Co-precipitated β-TrCP 
and AIMP2-DX2 with K-Ras were detected by western blotting.
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Figure 8. Schematic model
In normal condition, β-TrCP/GSK3β, K-Ras degradation complex, 
leads to the proteasome-dependent degradation of K-Ras (left). Binding 
overexpressed AIMP2-DX2, oncogeninc protein, to K-Ras blocks the 
approach of β-TrCP/GSK3β complex for protection the ubiquitination, 
resulting in stabilization of K-Ras. Interaction of two oncogenic 
proteins, K-Ras and AIMP2-DX2, makes the synergetic oncogenecity, 
leading to enhancement of cancer cell proliferation.
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Material and methods
Cell culture and material
Mammalian cells such as H460 in RPMI with HEPES (hyclone), HEK 293T 
in DMEM (hyclone) were cultured at 37˚C with CO2 5%. Strep-DX2 or 
strep-EV inducible H460 stable cell was cultured in RPMI with HEPES. 
Strep-tagged human AIMP2-DX2 was lab material. GFP-tagged human K-
Ras4A, K-Ras4B, N-Ras and H-Ras were gifted by Mark Philips (NY 
Univ.). HA-tagged Ub, Flag-tagged human K-Ras, and RFP-tagged DX2 
were lab materials. GFP-tagged GSK3β and Myc-tagged β-TrCP were gifted 
by Kang-Yell Choi (Yonsei Univ.) GFP-Ras isoforms containing point 
mutation of G12 or Q61 were cloned using the QuickChange®Ⅱ (Agilent), 
following the manufacturer’s instruction. , Protease Inhibitor and MG132 
were purchased from Calbiochem. Cycloheximide was purchased from 
Sigma-Aldrich. Antibody against Strep was purchased from IBA. The other 
primary antibodies using in this study were purchased from Santa Cruz 
Biotechnology. Secondary antibodies, Mouse (Thermo scientific 
Immunopure Ab, Host Goat-Anti, Antigen Mouse IgG [H+L], Cat 31430), 
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and Rabbit (Thermo scientific Immunopure Ab, Host Goat-Anti, Antigen 
Mouse IgG [H+L], Cat 31430) were used. Streptavidine Sepharose™ High 
Performance and Glutathione Sepharose were purchased from GE 
Healthcare.  
Western Blot
HEK 293T cell line was used. Lysis buffer (1% Triton X-100, 0.1% SDS, 
and protease inhibitor in PBS) was applied to the cells and it was incubated 
for 45 min at 4℃. The supernatant was taken after centrifuge, which was 
quantified with Bradford assay (BioRad, Cat. 500-0006). Final sample was 
maded by adding 5X laemmli sample buffer. Samples were boiled for 7min 
before gel running. After that, samples were loaded on 12% SDS-PAGE gel 
and separated by electrophoresis. Proteins at the gel were transferred to 
PVDF membranes from Merck Millipore for 100mins, 55mA per gel. 
Blocking with 5% skim milk based 0.5% TBS-T for 1hr was performed, 
followed by 1㎍/㎕ of primary antibody (1% skim milk) binding for 2hr at 
RT. Incubate with secondary antibody in 1:20000 was for 1hr at RT. The 
film was exposed normally 2 to 15min.
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RT-PCR
Transcript level of AIMP2-DX2 and Ras was measured by RT-PCR. RNA 
was gathered by H460, which was transfected with plasmid DNA, using 
RNeasy Mini kit from Qiagen as manufacturer’s instruction. 2㎍ of RNA 
was reverse-transcribed with M-MLV Reverse Transcriptase (Invitrogen), 
Random hexamer (Qiagen), dNTP (Takara), forward primer, reverse primer 
and reaction buffer. 













After synthesizing cDNA from the extracted RNA, transcript level of 
AIMP2-DX2 and Ras was measured using PCR Premix from Bioneer
through PCR.
Immunoprecipitation
HEK 293T cell line was lysed with 50mM Tris-HCl (pH7.4) buffer 
containing 100mM NaCl, 0.5% Triton X-100, 0.05% SDS, 10% glycerol, 
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1mM EDTA and protease inhibitor. To remove the nonspecific IgG bound 
proteins, protein extracts were incubated with normal IgG and protein 
agarose for 2hr and then centrifuged. The supernatants were mixed with 
specific antibody, incubated the mixture for 4hr at 4℃ with gentle agitation, 
added protein agarose. After agitation, precipitates were washed with the 
cold lysis buffer three times, and precipitates were dissolved in the SDS 
sample buffer and subjected to SDS-PAGE.  
Immunofluorescence staining
HEK 293T cell line was used. Cells were transfected with both GFP-Ras 
isoforms wild type or mutant type and mcherry-DX2. Cells were washed 
briefly with cold PBS. After incubation with the blocking buffer, 1% CAS, 
for 30min and mounted with mounting solution containing DAPI 
(ImmunoBioScience Corp.). The mounted samples were observed by 
confocal laser-scanning microscopy. 
GST fusion protein purification and pull down assay
GST-DX2 domain fragment proteins were purified as follows. BL21 
34
competent cells were transformed with each DNA and cultured in LB media 
containing ampicillin. The competent cells were induced by 1mM IPTG and 
cultured overnight at 18℃. The competent cells were centrifuged at 3,000 
rpm for 30min at 4℃. The pellet was resuspended by PBS containing 0.5% 
Triton X-100 and protease inhibitor and lysed by sonication on ice. The 
lysate was centrifuged at 13,000 rpm for 30min at 4℃. The supernatants 
were incubated with Glutathione Sepharose (GE Healthcare) overnight at 4℃
under rotary agitation. The purified proteins were quantified by InstantBlue.
Purified GST-tagged proteins containing beads were incubated with lysates, 
which were transfected HEK 293T cell lysates, overnight at 4℃ under 
rotary agitation. After agitation, precipitates were washed with the cold lysis 
buffer three times, and precipitates were dissolved in the SDS sample buffer 
and subjected to SDS-PAGE.
Ubiquitination assay 
The cells were pre-incubated with MG132 for 4hr (50μM), and were lysed 
with lysis buffer used in Western Blot. The interesting proteins were 
immunoprecipitated with specific antibody and subjected SDS-PAGE for 
immunoblotting to determine the amounts of ubiquitinated protein.
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Lenti-X Tet-One Inducible Expression System
The following are the steps required to create a doxycycline-inducible 
expression system using lentivirus. Strep-EV and Strep-DX2 were cloned 
into the pLVX-TetOne Vector using In-Fusion HD. Lentiviral supernatants 
were produced using the Lenti-X HTX Packaging System. H460 cells were 
transduced with TetOne virus. 
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국문초록
K-Ras 는 암 세포에서 가장 빈번하게 변형된 종양 형성 유전자로
잘 알려져 있다. 뿐만 아니라 암 환자의 생존률 감소에 영향을
미치며, 초기 진단을 통한 처방에도 어려움을 주는 요소이다. K-
Ras 가 암 치료에 중요한 타겟임에도, 암세포 내의 K-Ras 단백질
증가와 관련한 기전 연구가 잘 밝혀져 있지 않다. 우리는 본
연구를 통해, AIMP2-F 의 변성체로 알려진 종양 형성 유발인자인
AIMP2-DX2 가 K-Ras 의 단백질 안정화에 기여하는 데에 중요한
역할을 한다고 보고한다. 다양한 AIMP2-DX2 의 발현을 보이는
폐암 세포의 전사체 분석을 통하여, AIMP2-DX2 가 Ras 신호체계와
관련이 있음을 확인하였다. 또한 AIMP2-DX2 를 유도하는 in vitro
와 in vivo 모델을 통하여, AIMP2-DX2 를 유도함으로써 K-Ras 
안정화가 이루어지는 것을 확인하였다. AIMP2-DX2 GST-N 범위가
양전하를 띠는 K-Ras 의 hypervariable region 과 결합하는 것을
확인하였고, AIMP2-DX2 와의 결합을 통해 K-Ras 의 E3 ligase 로
알려진 β-TrCP 에 의한 ubiquitination 이 감소하는 것을 확인 할 수
있었다. 본 연구는 K-Ras 의 안정화가 AIMP2-DX2 와의 결합을
통하여 이루어질 수 있음을 제시하며, 이는 두 병리적인 종양형성
유전자 간의 상호 연결 관계를 밝힘으로써 암세포 성장을
촉진하는 데에 상승적인 역할을 함을 밝힌다.  
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